Aselizumab, also known as HuDreg-55, signifies a emerging monoclonal antibody designed to interact with C1q. Its mechanism of action utilizes modulating the initial complement pathway, likely offering https://aselizumabresearchgrade253657.newsyblog.com/219044/aselizumab-a-comprehensive-investigation-into-hudreg-55